Marsha Stanton, Ph.D., RN, Pernix Therapeutics Executive Director of Medical and Government Affairs, Awarded Prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing®
September 16, 2016 07:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced...
Pernix Therapeutics Announces the Issuance of Two New Orange Book Listed Patents for Zohydro® ER with BeadTek™
September 14, 2016 07:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the United States Patent and...
Pernix Therapeutics Announces Significant Presence at PAINWeek 2016
September 09, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Company’s Poster Presentation Highlighted Results of Study Evaluating Hepatic or Renal Impairment on the Pharmacokinetics of Zohydro® ERPernix Also Sponsored a Well-Attended Symposium Focused on...
Pernix Therapeutics Reports Second Quarter 2016 Financial Results and Business Update
August 11, 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
Net Revenue Increased 13% Sequentially Over First Quarter 2016 Recently Completed Reorganization of Management Team and Restructuring of Sales Force and Operations MORRISTOWN, N.J., Aug. 11, 2016...
Pernix Therapeutics Announces Reorganization of Senior Management Team
July 26, 2016 17:40 ET
|
Pernix Therapeutics Holdings, Inc.
John Sedor Appointed CEO on a Permanent Basis Company Names Pharmaceutical Industry Veteran, Dr. Graham Miao, as President & CFO Company Positioned to Maximize Value and Drive Revenue Growth...
Pernix Therapeutics Overcomes Challenge to Treximet® ‘183 Patent
May 09, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and...
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
May 05, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Pernix Prescriptions DirectTM Achieves Increased Penetration MORRISTOWN, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a...
Pernix Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
March 10, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Full Year 2015 Revenue Increases 44% Year-Over-Year to $176 MillionFull Year 2015 Adjusted EBITDA of $31.2 MillionMORRISTOWN, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings,...
Pernix Therapeutics Reports Third Quarter 2015 Financial Results
November 05, 2015 06:50 ET
|
Pernix Therapeutics Holdings, Inc.
Revenue Increases 54% Year-Over-Year Company Reiterates Financial Guidance MORRISTOWN, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or “the...
Pernix Therapeutics Reports Second Quarter 2015 Financial Results
August 06, 2015 06:50 ET
|
Pernix Therapeutics Holdings, Inc.
Revenues Increase Over 150% Year-Over-Year
Company Provides Updated Financial Guidance
MORRISTOWN, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)...